DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 1GG — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 1GG maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 1gg is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In a 1994 follow-up of 235 patients aged 16–70 enrolled from 1978 to 1992, two-year and four-year survival in dilated cardiomyopathy improved across three consecutive five-year periods. Group 1 (1978–1982, 26 patients) had 73.8% and 53.8% survival; group 2 (1983–1987, 65 patients) had 87.7% and 72.3%; group 3 (1988–1992, 144 patients) had 90.3% and 82.9% (P = 0.02). Patients in later groups were younger and less severely affected, but the survival improvement remained significant after stratification for disease severity. A progressively higher proportion of patients received ACE inhibitors and later beta blockers. In group 2, ACE inhibitor-treated patients showed better survival than untreated patients after stratification for heart failure severity. In group 3, beta blockers had a significant additive effect with conventional therapy: four-year survival in mild and moderate-to-severe heart failure patients treated with beta blockers, usually digitalis and ACE inhibitors, was 90% and 87.5% respectively.
A 2011 prospective cohort study of 373 patients (mean age 45, 21% black, 38% women) with recent-onset non-ischemic dilated cardiomyopathy (mean symptom duration 2.2 months) and at least moderately severe left ventricular systolic dysfunction reported outcomes with contemporary evidence-based therapies including beta-blockers. The abstract does not give specific survival or response rates but states that prognosis with these therapies was not previously known.
A 1989 review noted that the natural history of dilated cardiomyopathy varied from death within two years in 50% of patients to survival beyond ten years in 25%. The incidence was increasing, with at least 11,000 new cases per year in the United States at that time. Traditional therapy then included cardiac glycosides and diuretics. A 2016 review states that causative genetic mutations have been identified in more than 40 genes, and that dilated cardiomyopathy is characterised by ventricular dilation and progressive systolic dysfunction.
No abstract in this set reports a randomised controlled trial of any single drug for dilated cardiomyopathy. The 1994 study is observational and notes that patient characteristics changed over time, which partly explains the survival improvement. The 2011 study does not provide numerical outcomes. What is still missing is a large, modern, randomised trial that stratifies patients by genotype and stage of disease, and that is adequately funded to follow patients for long enough to detect differences in mortality and transplantation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Heart · 1994 · 76 citations · open access
Changing mortality in dilated cardiomyopathy
AbstractOBJECTIVE: To analyse the changes in mortality in dilated cardiomyopathy over the past 15 years and to identify the factors that might have influenced survival. DESIGN: Follow up study of 235 patients (aged 16-70) systematically enrolled on a register from 1 January 1978 to 31 December 1992. SETTING: Hospital department of cardiology. PATIENTS: Three groups corresponding to three periods of 5 years: group 1 (diagnosis between 1 January 1978 and 31 December 1982) 26 patients; group 2 (diagnosis between 1 January 1983 and 31 December 1987) 65 patients; and group 3 (diagnosis between 1 January 1988 and 31 December 1992) 144 patients. MAIN OUTCOME MEASURES: Death or heart transplantation. RESULTS: Two and four year survival was 73.8% and 53.8% in group 1, 87.7% and 72.3% in group 2, and 90.3% and 82.9% in group 3 (P = 0.02). During the 15 years of the study period the number of cases increased progressively and the baseline clinical characteristics changed (that is, patients were younger and less severely affected), partly explaining the improvement in survival. None the less, the three mortality curves tended to diverge progressively and the improvement in survival in the different groups was still significant after stratification for the severity of the disease, suggesting that treatment had a sustained effect. A progressively higher proportion of patients were treated with angiotensin converting enzyme (ACE) inhibitors and more recently with beta blockers. In group 2, after stratification for the severity of heart failure, patients who were treated with ACE inhibitors showed a better survival than patients who were not. Furthermore, analysis of group 3 showed that beta blockers had a significant additive effect with conventional therapy both by intention to treat and actual treatment. Four year survival in patients with mild and moderate to severe heart failure treated with beta blockers, and usually digitalis and ACE inhibitors, was respectively 90% and 87.5%. CONCLUSIONS: The improvement in the survival of patients with dilated cardiomyopathy over the past 15 years may be explained by earlier diagnosis, new treatments, and a change in the clinical characteristics of the patients at enrolment.
Journal of Cardiovascular Medicine · 2016 · 15 citations
Genetic bases of dilated cardiomyopathy
AbstractCardiomyopathies represent a wide and heterogeneous group of diseases wherein a genetic cause has been consistently identified.Dilated cardiomyopathy (DCM) is characterized by ventricular dilation and progressive systolic dysfunction, and it is the most common form of cardiomyopathy.Causative genetic mutations have been identified in more than 40 genes encoding proteins belonging to different cellular structures and pathways.A great diversity of pathways has been implied in the pathogenesis of DCM, depending on the affected genes and on the dislodged intracellular structures or mechanisms.This review describes the major genes and focus on the pathophysiologic mechanisms of DCM, with a special consideration of the most recent discoveries in the field.
New England Journal of Medicine · 1989 · 10 citations
Immunosuppression for Dilated Cardiomyopathy
AbstractThe diagnosis of dilated cardiomyopathy is made when left ventricular dilatation and systolic dysfunction, with normal wall thickness, occur in the absence of coronary artery, valvular, or pericardial disease.1 The right ventricle is also often involved. The natural history of the disease varies from a course progressing to death within 2 years in 50 percent of afflicted patients2 to survival for more than 10 years in 25 percent. The incidence of dilated cardiomyopathy is increasing; at least 11,000 new cases are diagnosed each year in the United States. The traditional approach to therapy includes cardiac glycosides and diuretics. Although increased . . .
Contemporary Treatment Improves Outcomes of Recent-Onset Cardiomyopathy
AbstractStudies of recent-onset dilated cardiomyopathy suggest varied outcomes, but the prognosis with contemporary evidence-based therapies, including beta-blockers, is not known. In this multicenter prospective cohort study, researchers evaluated outcomes among 373 patients (mean age, 45; 21% black; 38% women) with recent-onset, nonischemic, dilated cardiomyopathy (mean symptom duration, 2.2 months) and left ventricular systolic dysfunction of at least moderate severity (mean left …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
